View Item 

Amyloid ß–associated cognitive decline in the absence of clinical disease progression and systemic illness

Access Status
Fulltext not available
Authors
Harrington, K.
Lim, Y.
Ames, D.
Hassenstab, J.
Laws, Simon
Martins, R.
Rainey-Smith, S.
Robertson, J.
Rowe, C.
Salvado, O.
Doré, V.
Villemagne, V.
Snyder, P.
Masters, C.
Maruff, P.
Date
2017
Type
Journal Article

Metadata
Show full item record
Citation
Harrington, K. and Lim, Y. and Ames, D. and Hassenstab, J. and Laws, S. and Martins, R. and Rainey-Smith, S. et al. 2017. Amyloid ß–associated cognitive decline in the absence of clinical disease progression and systemic illness. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring. 8: pp. 156-164.
Source Title
Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring
DOI
ISSN
School
School of Pharmacy and Biomedical Sciences
URI
Collection
Abstract

© 2017 The Authors Introduction High levels of amyloid ß (Aß) are associated with cognitive decline in cognitively normal (CN) older adults. This study investigated the nature of cognitive decline in healthy individuals who did not progress to mild cognitive impairment or dementia. Method Cognition was measured over 72 months and compared between low (Aß-) and high (Aß+) CN older adults (n = 335) who did not progress to mild cognitive impairment or dementia and who remained free of severe or uncontrolled systemic illness. Results Compared to the Aß- group, the Aß+ group showed no cognitive impairment at baseline but showed substantial decline in verbal learning, episodic memory, and attention over 72 months. Discussion Moderate cognitive decline, particularly for learning and memory, was associated with Aß+ in CN older adults in the absence of clinical disease progression and uncontrolled or serious comorbid illness.